Model-Based Meta-Analysis (MBMA) at GSK: Real-World Impact on Strategy and Trials
GSK shares real-world case studies on how Model-Based Meta-Analysis (MBMA) supports dose selection, virtual control…
CertaraJuly 31, 2025
Recapping a record-breaking 2025 Krakow HTA Symposium
We cover the key takeaways from CERTAINTY 2025, including the power of Model-Informed Drug Development…
Simona ColucciJuly 30, 2025
Optimizing Dosing and Regulatory Outcomes in Duchenne Muscular Dystrophy (DMD) Drug Development
Certara supported DMD drug development for Givinostat, helping Italfarmaco with pharmacometric and regulatory strategy.
CertaraJuly 29, 2025
ADNCA Explained: The Next Generation of Non-Compartmental Analysis and the Top Questions Answered
ADNCA is transforming non-compartmental analysis by standardizing workflows, enhancing regulatory confidence, and enabling scalable automation.…
CertaraJuly 23, 2025
The end of animal testing? Transitioning to models is promising — but no silver bullet
The FDA has stated that the pharma industry must transition to using in vitro assays,…
CertaraJuly 21, 2025
